Over the past decades, significant progress has been made in understanding the pathogenesis of chronic inducible urticaria (CIndU). Provocation tests continue to play an important role in confirming the diagnosis. For patients who do not achieve disease control despite H1 antihistamines or omalizumab, numerous biologics and small molecules are currently being investigated in clinical trials, most – but not all – of which are directed against new therapeutic targets.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- DERMATOLOGIE PRAXIS
Related Topics
You May Also Like
- From genome profiles to targeted therapies
Advances in breast cancer therapy in the age of molecular diagnostics
- Current overview of evidence, mechanisms and clinical implications
Apolipoprotein E and neuropsychiatric symptoms in neurocognitive disorders
- Parkinson's disease
Individual therapy management for an optimized outcome – an update
- Rare pulmonary syndromes
Yellow nail and Swyer-James syndrome
- Latent autoimmune diabetes in adults (LADA)
Looks like type 2, but is type 1
- Treatment of vitiligo
Focus on patient perspective and disease activity
- Vaccine-preventable respiratory diseases
RSV and pneumococci: recommendations for risk groups
- Circadian rhythm in asthma